Anatara Lifesciences Balance Sheet Health

Financial Health criteria checks 6/6

Anatara Lifesciences has a total shareholder equity of A$1.4M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$1.7M and A$306.8K respectively.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	n/a
Cash	AU$982.11k
Equity	AU$1.36m
Total liabilities	AU$306.85k
Total assets	AU$1.67m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: ANR's short term assets (A$1.7M) exceed its short term liabilities (A$304.2K).

Long Term Liabilities: ANR's short term assets (A$1.7M) exceed its long term liabilities (A$2.7K).

Debt to Equity History and Analysis

Debt Level: ANR is debt free.

Reducing Debt: ANR has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANR has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ANR is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.

Anatara Lifesciences Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies